Saturday 17 October 2026 Export LKFT’s income statement to Excel — free account

Lakefront Biotherapeutics - Sponsored ADR

Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024. In the quarter to June 2026, revenue fell 95.4%, EPS grew 198.9% and free cash flow grew 18.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

29.90 0.03 −0.10%

Follow LKFT

Alert me

Market cap: $2.0B
P/E: 0.0×
Fwd P/E: −10.6×
Dividend yield: —
F-score: 6/9
Altman Z: 8.43
Beneish M: 0.34
Dividend safety: n/a

Overview Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 25.60%

Capital & Financial Ratios $m

Market Cap 1,970.00

Revenue 282.04

Net Income (652.45)

Free Cash Flow (524.53)

Net Debt (2,598.37)

Current Ratio 32.84

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (10.60)

P/S ratio 6.98

P/B ratio 0.52

Past 5Y EPS Growth —

This Y EPS Growth (144.34%)

Next Y EPS Growth 5.26%

Next Y revenue growth (89.54%)

Next 5Y EPS Growth 47.44%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 46.41%

10-year low 10-year high

P/B against its own 10 years 5.60%

10-year low 10-year high

EV/FCF against its own 10 years 4.80%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3,988	3,418	3,392	2,604
Receivables	71	95	59	65
Inventory	80	55	25	10
Other	40	46	8	6
	4,179	3,614	3,484	2,685

	2023	2024	2025	Q'26
Payables	146	107	118	77
ST’ Debt	—	—	—	—
Other	35	—	51	2
	463	363	173	82

Compound Annual Growth %

	10y	5y	3y
Sales	34.03%	15.75%	33.21%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	24.62%	3.72%	11.22%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	—	—	—	—
’25	79	—	—	—	1,258
’24	68	—	—	—	298
’23	194	163	128	—	259
’22	153	146	137	96	532
’21	150	184	76	164	574
’20	118	130	168	190	606

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(97)	(39)	—	—	—
’25	(41)	(127)	(245)	—	(291)
’24	(133)	(70)	(287)	—	(346)
’23	(101)	(133)	(369)	—	(439)
’22	(70)	(147)	(106)	(204)	(527)
’21	(146)	(99)	(156)	(195)	(596)
’20	(76)	(155)	(225)	(32)	(488)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(95)	(38)	—	—	—
’25	(46)	(132)	(260)	—	(306)
’24	(140)	(141)	(371)	—	(435)
’23	(105)	(139)	(379)	—	(458)
’22	(80)	(155)	(116)	(214)	(566)
’21	(157)	(112)	(174)	(222)	(665)
’20	(90)	(168)	(251)	(83)	(592)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.26	—	—	—	—
’25	(2.45)	—	—	—	5.51
’24	1.49	—	—	—	1.21
’23	0.38	0.09	0.41	—	3.47
’22	(0.22)	(0.31)	0.33	(3.23)	(3.50)
’21	0.17	(1.18)	(1.17)	0.31	(1.87)
’20	(0.86)	(1.95)	(1.46)	(1.09)	(5.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	37.03	63.69	85.00	89.45	93.01	46.41	37.24	31.86	24.16	22.36	Analyst estimates 2026–2028 Powerpack
	High	73.37	104.12	122.28	217.29	274.03	113.71	72.11	48.07	42.46	37.78
People
People	Employees	508	600	725	1,003	1,304	1,309	1,338	1,123	704	452
	Revenue/emp, $m	0.33	0.29	0.52	1.00	0.46	0.44	0.40	0.23	0.42	2.78
Income, $m
Income, $m	Revenue	168	176	375	1,003	606	574	532	259	298	1,258
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	99.66	97.61	100.00	87.35	97.33
	EBT	60	(131)	(34)	168	(354)	(146)	(227)	6	(3)	340
	EBT margin, %	35.78	(74.08)	(9.19)	16.75	(58.42)	(25.37)	(42.58)	2.35	(1.12)	27.05
	Net income	60	(131)	(35)	168	(349)	(122)	(230)	229	80	363
	Depreciation	5	5	6	14	21	41	69	47	49	63
Per share, $
Per share, $	Revenue	3.67	3.56	7.20	17.42	9.31	8.76	8.10	3.94	4.53	19.10
	Earnings	1.29	(2.64)	(0.66)	2.91	(5.36)	(1.87)	(3.50)	3.47	1.21	5.51
	Cash flow	5.80	(3.36)	(3.23)	62.37	(7.50)	(9.10)	(8.03)	(6.67)	(5.26)	(4.42)
	Capex	(0.12)	(0.17)	(0.31)	(0.89)	(1.60)	(1.05)	(0.58)	(0.28)	(1.35)	(0.23)
	Free cash flow	5.68	(3.53)	(3.54)	61.49	(9.10)	(10.15)	(8.61)	(6.95)	(6.60)	(4.65)
	Book value	18.37	23.12	27.52	55.90	46.87	47.75	40.51	45.92	47.57	55.56
	Shares, m	46	49	52	58	65	66	66	66	66	66
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	80.17	0.00	0.00	0.00	0.00	11.59	0.00
	P/S	47.10	50.39	12.74	11.88	10.63	6.30	5.47	4.69	3.28	4.92
	P/B	3.59	3.59	3.33	3.70	2.11	1.15	1.09	0.95	0.58	0.75
	EV/Sales	29.35	33.88	8.68	5.45	0.95	(3.37)	(2.60)	(2.44)	(3.44)	(3.21)
	EV/FCF	12.64	25.27	(17.65)	1.54	(0.97)	2.91	2.45	1.69	1.84	1.74
Cash, $m
Cash, $m	Operating cash flow	265	(166)	(168)	3,594	(488)	(596)	(527)	(439)	(346)	(291)
	Capex	(5)	(8)	(16)	(51)	(104)	(68)	(38)	(18)	(89)	(15)
	Free cash flow	260	(175)	(184)	3,542	(592)	(665)	(566)	(458)	(435)	(306)
Balance, $m
Balance, $m	Working capital	1,000	1,160	1,310	5,929	5,408	5,082	3,913	3,716	3,251	3,311
	Total debt	0	0	—	22	28	23	15	5	—	6
	Net debt	(1,084)	(1,301)	(1,524)	(6,452)	(5,868)	(5,542)	(4,298)	(3,982)	(3,418)	(3,386)
	Shareholders’ equity	840	1,144	1,434	3,221	3,050	3,127	2,661	3,026	3,135	3,661
Returns, %
Returns, %	ROA	7.07	(9.86)	(2.19)	3.95	(5.24)	(1.93)	(4.13)	4.72	1.74	8.72
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	75.88
	ROE	9.60	(13.19)	(2.68)	7.21	(11.13)	(3.95)	(7.94)	8.06	2.60	10.68

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
VCEL Vericel Corporation	$2.1B	83.6×	76.8×	+22.48% (above 0%: growing)	n/m	+17,503.70% (above 0%: growing)	72.82%	0.56%	Compare
PHVS Pharvaris N.V.	$2.1B	— (loss-making)	—	—	n/m	−17.31% (below 0%: shrinking)	0.00%	0.00%	Compare
VERA Vera Therapeutics, Inc.	$2.1B	— (loss-making)	—	—	n/m	−82.47% (below 0%: shrinking)	0.00%	0.00%	Compare
IMNM Immunome, Inc.	$2.1B	— (loss-making)	— (loss-making)	+69.84% (above 0%: growing)	n/m	−26.96% (below 0%: shrinking)	100.00%	0.00%	Compare
LKFT Lakefront Biotherapeutics - Sponsored ADR	$2.0B	— (loss-making)	— (loss-making)	−95.35% (below 0%: shrinking)	+198.85% (above 0%: growing)	+18.22% (above 0%: growing)	25.95%	(982.91%)
AGIO Agios Pharmaceuticals, Inc.	$1.9B	— (loss-making)	— (loss-making)	+259.25% (above 0%: growing)	n/m	+24.97% (above 0%: growing)	93.30%	(247.07%)	Compare
MLYS Mineralys Therapeutics, Inc.	$1.9B	— (loss-making)	—	—	n/m	−7.91% (below 0%: shrinking)	—	0.00%	Compare
SRPT Sarepta Therapeutics, Inc.	$1.9B	— (loss-making)	4.4×	−34.34% (below 0%: shrinking)	n/m	−14.48% (below 0%: shrinking)	62.77%	3.31%	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
Median of peers	$2.0B	—	—	+22.48%	—	−11.20%	62.77%	0.00%

All 614 Biotechnology stocks →

Lakefront Biotherapeutics - Sponsored ADR (LKFT) key facts

Strength: Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
Lakefront Biotherapeutics - Sponsored ADR (LKFT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, LKFT traded at $29.90, a market capitalization of $2.0 billion.
Return on equity was 10.7% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 8.43 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.